2024-02-08 09:55:00 ET
Summary
- Avid Bioservices was by far our biggest loser in 2023.
- Avid recently issued an investor presentation that provides more insights into their late phase pipeline and backlog continues to grow.
- CDMO has proven that it is a good operator, and the pipeline is robust.
- In all cases, there is plenty to go around, and insiders seem to agree as there has been insider buying recently.
The following segment was excerpted from this fund letter.
Avid Bioservices ( CDMO )
Avid, our large molecule Contract Drug Manufacturing Organization, was by far our biggest loser in 2023....
Read the full article on Seeking Alpha
For further details see:
Laughing Water Capital - Avid Bioservices: Substantial Future Earnings Power, Strong Competitive Position